Allogene replaces Zai Lab-bound Rafael Amado with Zachary Roberts

3 January 2023
allogene_therapeutics_large

CAR-T therapy company Allogene Therapeutics (Nasdaq: ALLO) has swiftly named its replacement for executive vice president of research and development Rafael Amado, who has resigned to join Sino-American firm Zai Lab (Nasdaq: ZLAB)."I am excited to work again with some of the pioneers of cell therapy"

Zachary Roberts will replace the departing Dr Amado, who leaves after more than three years with Allogene in a career that has also taken in Adaptimmune (Nasdaq: ADAP), GSK (LSE: GSK) and Amgen (Nasdaq: AMGN), to become Zai Lab's president, head of global oncology research and development.

Prior to joining Allogene, Dr Roberts was chief medical officer of Instil Bio (Nasdaq: TIL), where he led the development of both clinical and pre-clinical programs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology